Prof. de Bono is Regius Professor of Cancer Research, and Professor in Experimental Cancer Medicine at The Institute of Cancer Research, London, and Director of the joint Drug Development Unit at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London.
Prof. de Bono is a world leader in prostate cancer research, leading advancements in the treatment of prostate cancer through trials of abiraterone, cabazitaxel, and enzalutamide. He has also led the clinical development of multiple PARP inhibitors, including talazoparib, niraparib and olaparib. He also led on the identification of germline and somatic DNA repair defects in lethal prostate cancer. Prof. de Bono earned his M.D. and Ph.D. from Glasgow University, and he is a Fellow of the Royal College of Physicians, a Member of the Malta Order of Merit and received the prestigious ESMO Award in 2012.